Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRSPNASDAQ:NTLA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRSPCRISPR Therapeutics$38.25+1.4%$39.09$30.04▼$67.88$3.30B1.851.65 million shs1.65 million shsNTLAIntellia Therapeutics$8.84+2.3%$8.38$5.90▼$28.18$915.09M2.232.42 million shs3.46 million shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRSPCRISPR Therapeutics-2.43%-3.53%+13.85%-9.28%-29.88%NTLAIntellia Therapeutics-2.59%+5.62%+29.73%-16.28%-61.60%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRSPCRISPR Therapeutics3.0289 of 5 stars4.21.00.00.02.33.30.6NTLAIntellia Therapeutics4.6683 of 5 stars4.31.00.04.73.92.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRSPCRISPR Therapeutics 2.48Hold$73.1191.12% UpsideNTLAIntellia Therapeutics 2.65Moderate Buy$36.68314.98% UpsideCurrent Analyst Ratings BreakdownLatest NTLA and CRSP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2025NTLAIntellia TherapeuticsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradePeer Perform ➝ Outperform$21.004/9/2025CRSPCRISPR TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$84.00 ➝ $84.003/5/2025NTLAIntellia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.003/4/2025NTLAIntellia TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$90.00 ➝ $50.002/28/2025NTLAIntellia TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$55.00 ➝ $26.002/28/2025NTLAIntellia TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$12.00 ➝ $14.002/28/2025NTLAIntellia TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$60.00 ➝ $50.002/28/2025NTLAIntellia TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$91.00 ➝ $68.002/28/2025NTLAIntellia TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Sell$9.002/28/2025NTLAIntellia TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral$45.00 ➝ $13.002/19/2025CRSPCRISPR TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral(Data available from 5/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRSPCRISPR Therapeutics$35M94.38N/AN/A$22.52 per share1.70NTLAIntellia Therapeutics$57.88M15.81N/AN/A$11.73 per share0.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRSPCRISPR Therapeutics-$366.25M-$4.37N/AN/AN/A-981.54%-18.46%-15.79%5/6/2025 (Estimated)NTLAIntellia Therapeutics-$481.19M-$5.25N/AN/AN/AN/A-49.34%-40.27%5/8/2025 (Estimated)Latest NTLA and CRSP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025CRSPCRISPR Therapeutics-$1.26N/AN/AN/AN/AN/A5/8/2025Q1 2025NTLAIntellia Therapeutics-$1.26N/AN/AN/A$11.39 millionN/A2/11/2025Q4 2024CRSPCRISPR Therapeutics-$1.15-$0.44+$0.71-$0.44N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRSPCRISPR TherapeuticsN/AN/AN/AN/AN/ANTLAIntellia TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRSPCRISPR TherapeuticsN/A22.0722.07NTLAIntellia TherapeuticsN/A6.736.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRSPCRISPR Therapeutics69.20%NTLAIntellia Therapeutics88.77%Insider OwnershipCompanyInsider OwnershipCRSPCRISPR Therapeutics4.10%NTLAIntellia Therapeutics3.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRSPCRISPR Therapeutics47386.36 million82.26 millionOptionableNTLAIntellia Therapeutics600103.52 million98.59 millionOptionableNTLA and CRSP HeadlinesRecent News About These CompaniesMarshall Wace LLP Invests $1.11 Million in Intellia Therapeutics, Inc. (NASDAQ:NTLA)May 2 at 3:52 AM | marketbeat.comRenaissance Technologies LLC Purchases New Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)May 2 at 3:33 AM | marketbeat.comIntellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company UpdatesMay 1 at 11:09 AM | finance.yahoo.comEarnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to DeclineMay 1 at 11:06 AM | zacks.comIntellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 50-Day Moving AverageMay 1 at 10:30 AM | zacks.comPDT Partners LLC Buys 312,794 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)May 1 at 8:20 AM | marketbeat.comIntellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company UpdatesMay 1 at 7:30 AM | globenewswire.comAquatic Capital Management LLC Raises Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)May 1 at 6:12 AM | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Shares Gap Up - Should You Buy?April 30 at 12:17 PM | marketbeat.comCathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtApril 30 at 10:15 AM | fool.comWhy Intellia Therapeutics, Inc.’s (NTLA) Stock Is Up 5.05%April 29 at 12:50 PM | aaii.comWall Street Analysts Think Intellia Therapeutics (NTLA) Could Surge 392.81%: Read This Before Placing a BetApril 29 at 10:55 AM | zacks.comRaymond James Financial Inc. Makes New Investment in Intellia Therapeutics, Inc. (NASDAQ:NTLA)April 28, 2025 | marketbeat.comFY2025 Earnings Estimate for NTLA Issued By Zacks ResearchApril 27, 2025 | marketbeat.comFY2025 Earnings Forecast for NTLA Issued By Zacks ResearchApril 27, 2025 | americanbankingnews.comBank of Montreal Can Purchases New Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)April 25, 2025 | marketbeat.comWells Fargo & Company MN Purchases 76,872 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)April 25, 2025 | marketbeat.comLawsuit for Investors in shares of Intellia Therapeutics, Inc. ...April 23, 2025 | gurufocus.comIntellia Therapeutics (NASDAQ:NTLA) Trading Up 10.1% - Still a Buy?April 23, 2025 | marketbeat.comLawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders FoundationApril 23, 2025 | prnewswire.comWolfe Research Upgrades Intellia Therapeutics (NASDAQ:NTLA) to OutperformApril 23, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNTLA and CRSP Company DescriptionsCRISPR Therapeutics NASDAQ:CRSP$38.25 +0.52 (+1.38%) Closing price 04:00 PM EasternExtended Trading$38.38 +0.13 (+0.33%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Intellia Therapeutics NASDAQ:NTLA$8.84 +0.20 (+2.31%) Closing price 04:00 PM EasternExtended Trading$9.02 +0.18 (+2.04%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amazon Earnings: 2 Reasons to Love It, 1 Reason to Be Cautious Meta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2 Is It Time to Load Up on Bond ETFs? Palantir Earnings: 1 Bullish Signal and 1 Area of Concern Roblox Stock Gains Momentum and Can Top $100 in 2025 Microsoft Crushes Earnings, What’s Next for MSFT Stock? 3 Biotech Giants Gaining From U.S. Sales and Policy Shifts McDonald’s Insiders Sell Shares! Investors Should Do the Opposite Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
